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Abstract
Background: Proteins are involved in many interactions with other proteins leading to networks
that regulate and control a wide variety of physiological processes. Some of these proteins, called
hub proteins or hubs, bind to many different protein partners. Protein intrinsic disorder, via
diversity arising from structural plasticity or flexibility, provide a means for hubs to associate with
many partners (Dunker AK, Cortese MS, Romero P, Iakoucheva LM, Uversky VN: Flexible Nets:
The roles of intrinsic disorder in protein interaction networks. FEBS J 2005, 272:5129-5148).
Results: Here we present a detailed examination of two divergent examples: 1) p53, which uses
different disordered regions to bind to different partners and which also has several individual
disordered regions that each bind to multiple partners, and 2) 14-3-3, which is a structured protein
that associates with many different intrinsically disordered partners. For both examples, three-
dimensional structures of multiple complexes reveal that the flexibility and plasticity of intrinsically
disordered protein regions as well as induced-fit changes in the structured regions are both
important for binding diversity.
Conclusions: These data support the conjecture that hub proteins often utilize intrinsic disorder
to bind to multiple partners and provide detailed information about induced fit in structured
regions.
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Background
Protein-protein interaction (PPI) networks integrate vari-
ous biological signals including those used for energy gen-
eration, cell division and growth to give a few notable
examples. The architectures of the PPI networks indicate
that they are nearly scale free [1-8]. That is, a log-log plot
of the number of nodes versus the number of links (or
interactions) at each node gives a straight line with a neg-
ative slope. The negative slope means that these sets of
interactions contain a few proteins (hubs) with many
links and many proteins (non-hubs) with only a few links.
The term ‘hub protein’ is relative to the other proteins in
a given PPI network, with no agreed upon number of links
separating hubs and non-hubs.
Several networks such as the internet, cellular phone sys-
tems, social interactions, author citations, and so on,
exhibit scale-free architecture. With regard to PPIs, scale-
free network architecture is suggested to provide several
biological advantages. For example, given the small frac-
tion of hub proteins, random deleterious mutations will
more likely occur in non-hub proteins. The elimination of
the functions of such non-hub proteins typically have
small effects and so, generally, are not serious. In contrast,
a deleterious mutation of a hub protein is more likely to
be lethal [4-9]. Another advantage is that signals can
traverse these networks in a small number of steps, so sig-
nal transduction efficiency is improved compared to that
expected for random networks [7].
Understanding PPI network evolution across different
species is an important problem [10-13]. From this body
of work, hub proteins appear to evolve more slowly than
non-hub proteins, an observation that is consistent with
Fisher's classic proposal that pleiotropy constrains evolu-
tion [14,15]. Some proteins have multiple, simultaneous
interactions (“party hubs”) [16] while others have multi-
ple, sequential interactions (“date hubs”) [16]. Date hubs
appear to connect biological modules to each other [17]
while party hubs evidently form scaffolds that assemble
functional modules [16].
The idea that PPI networks use scale-free network topol-
ogy is receiving considerable attention, but some caution
is in order. Currently constructed networks are noisy, with
both false positive and false negative interactions [8,18-
20]. Also, network coverage to date [21,21-24] is not suf-
ficient to prove scale-free architecture [25]. Whether PPI
networks are truly scale-free or only approximately so, it
nevertheless appears to be true that a relatively small
number of proteins interact with many partners, either as
date hubs or party hubs, while many proteins interact
with just a few partners.
The ability of a protein to bind to multiple partners was
suggested to involve new principles [26]. Indeed, neither
the lock-and-key [27] nor the original induced-fit [28]
readily explains how one protein can bind to multiple
partners. Note that the original induced fit mechanism
was defined as changes in a structured binding site upon
binding to the partner [28], changes that are analogous to
a glove altering its shape to fit a hand. On the other hand,
both theoretical and experimental studies over many
years suggested that natively unstructured or intrinsically
disordered proteins form multi-structure ensembles that
present different structures for binding to different part-
ners [29-35]. Based on these prior studies, we proposed
that molecular recognition via disorder-to-order transi-
tions provides a mechanism for hub proteins to specifi-
cally recognize multiple partners [36]. We pointed out
earlier that intrinsic disorder could enable one protein to
associate with multiple partners (one-to-many signaling)
and could also enable multiple partners to associate with
one protein (many-to-one signaling) [35].
Recent bioinformatics studies support the importance of
protein disorder for hubs [37-41]. While disorder appears
to be more clearly associated with date hubs [39,41] than
with party hubs, some protein complexes clearly use long
regions of disorder as a scaffold for assembling an inter-
acting group of proteins [42,42-50]. Thus, the importance
of disorder for party hubs needs to be examined further.
Additional evidence for the importance of disorder for
highly connected hub proteins comes from a structure-
based study of the yeast protein interaction network [51].
The authors considered only interactions that could be
mediated by domains with known structures and found
that the degree distribution of the resulting network con-
tained no proteins with more than 14 interactions, which
is more than an order of magnitude less than is observed
in one unfiltered, high confidence dataset (Jake Chen,
personal communication). This result indicates that a
structure-based view of hub proteins is insufficient to
explain the multitude of partners that interact with hub
proteins.
To improve understanding of the use of disorder for bind-
ing diversity, we studied two prototypical examples: p53
and 14-3-3. Both are hubs that are clearly involved in cru-
cial biological functions. For example, p53 is a key player
in a large signaling network involving the expression of
genes carrying out such processes as cell cycle progression,
apoptosis induction, DNA repair, response to cellular
stress, etc. [52]. Loss of p53 function, either directly
through mutation or indirectly through several other
mechanisms, is often accompanied by cancerous transfor-
mation [53]. Cancers with mutations in p53 occur in
colon, lung, esophagus, breast, liver, brain, reticuloen-
dothelial tissues and hemopoietic tissues [53]. The p53BMC Genomics 2008, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2164/9/S1/S1
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protein induces or inhibits over 150 genes, including p21,
GADD45, MDM2, IGFBP3, and BAX[54].
The four regions or (not necessarily structured) domains
in p53 are the N-terminal transcription activation
domain, the central DNA binding domain, the C-terminal
tetramerization domain, and the C-terminal regulatory
domain. The last two could be considered to be a single C-
terminal domain with two subregions. The transactiva-
tion region interacts with TFIID, TFIIH, Mdm2, RPA, CBP/
p300 and CSN5/Jab1 among many other proteins [52].
The C-terminal domain interacts with GSK3β, PARP-1,
TAF1, TRRAP, hGcn5, TAF, 14-3-3, S100B(ββ) and many
other proteins [55].
As for 14-3-3 proteins, they contribute to a wide range of
crucial regulatory processes including signal transduction,
apoptosis, cell cycle progression, DNA replication, and
cell malignant transformation [56]. These activities
involve 14-3-3 interactions with various proteins in a
phosphorylation-dependent manner. More than 200 pro-
teins have been shown to interact with members of 14-3-
3 family [57-59], with these 14-3-3-interacting proteins
amounting to approximately 0.6% of the human pro-
teome [59]. One proposed functional model is that 14-3-
3 binds to the specific target as a molecular anvil causing
conformational changes in the partner. In their turn, these
changes can affect enzymatic (biological) activity of a tar-
get protein, or mask or reveal specific motifs that regulate
its localization, activity, phosphorylation state, and/or
stability [60].
The 14-3-3 protein has at least nine sequence isomers,
called α, β, γ, δ, ε, η, σ, τ, and ζ [61]. All isomers are struc-
tured dimers with grooves that bind to more than 200 dif-
ferent partners, and the different partners have different
sequences for their binding regions. Screening experi-
ments have identified individual peptides that bind to all
the different isomers, suggesting that the binding grooves
in the different isomers have some common features [62].
A recent bioinformatics study suggests that the partners of
14-3-3 utilize intrinsic disorder for binding [63].
The interactions of p53 and 14-3-3 with their partners as
reported previously [61,64-79] are examined herein but
from an order-disorder point of view. In the case of p53,
different regions in the disordered tails enable this protein
to bind to multiple partners at the same time. In addition,
one single region of disorder adopts clearly different sec-
ondary structures and uses the same amino acids to differ-
ent extents in different binding interactions. For this case
the plasticity of the disordered region clearly enables the
binding to multiple partners. In the case of 14-3-3, the dif-
ferent partners have distinct sequences. Their interactions
with 14-3-3 show characteristics, such as hydrogen bonds
between side chains of 14-3-3 and the backbone of the
partners and such as hydrogen bonds between the back-
bone of the partners and water, indicating that the two
partners were very likely unfolded in water just prior to
association with 14-3-3. The distinct sequences of the
partners do not adopt identical backbone structures, and
the various side chain interactions between 14-3-3 and
the two different partners involve induced-fit adjustments
of the 14-3-3 structure. Overall, these studies show how
the plasticity of disordered proteins is used to enable the
binding diversity of hub proteins, both for a single disor-
dered region binding to multiple partners and for multi-
ple disordered regions binding to the same partner. An
earlier, less complete version of this work was reported at
the Biocomp’07 meeting [80].
Results
Intrinsic disorder and the molecular interactions of p53
The p53 molecule interacts with many other proteins in
order to carry out its signal transduction function. A
number of these are downstream targets, such as tran-
scription factors, and others are activators or inhibitors of
p53's transactivation function. Many of these interactions
have been mapped to regions of the p53 sequence (Figure
1, gray boxes): the N-terminal domain (i.e., the transacti-
vation domain), the C-terminal domain (i.e., the regula-
tory domain), and the DNA binding domain (DBD).
These domains have also been characterized in terms of
their structure or lack thereof (Figure 1, red (disordered)
and blue (structured) segments), where the DNA binding
domain is intrinsically structured and the terminal
domains are intrinsically disordered [81,82]. While the
tetramerization domain is structured, the structure is
acquired upon the formation of the complex. Addition-
ally, multiple different posttranslational modifications
have been identified in p53 (Figure 1, vertical ticks). These
modifications are relevant here because they are a com-
mon method for altering protein interactions.
Comparing the regions of order and disorder reveals a
strong bias towards the localization of the interactions
within the intrinsically disordered regions. Overall, 60/84
= 71% of the interactions are mediated by intrinsically dis-
ordered regions in p53. A bias toward intrinsically disor-
dered regions is even more pronounced in the sites of
posttranslational modifications, with 86%, 90%, and
100% of observed acetylation, phosphorylation, and pro-
tein conjugation sites, respectfully, found in the disor-
dered regions. This is consistent with previous
observation of a strong bias for post translational modifi-
cations toward intrinsically disordered regions [83]. This
concentration of functional elements within intrinsically
disordered regions compares to just 29% of the residues
being disordered [36]. Clearly, p53 exhibits a highlyBMC Genomics 2008, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2164/9/S1/S1
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biased use of disordered regions for mediating and mod-
ulating interactions with other proteins.
In addition to experimentally characterized disorder, pre-
dictions of intrinsic disorder for p53 using both PONDR
VL-XT [84] and VSL2 predictions [85] were carried out
Summary of p53 interactions and structure Figure 1
Summary of p53 interactions and structure. Dark gray boxes indicate the approximate binding regions of p53's known 
binding partners. The regions of p53 represented in structure complexes in PDB are represented by horizontal bars, labeled 
with the name of the binding partner. For the DBD, the extent of the globular domain is indicated by the light grey box, where 
the internal horizontal bars indicate regions involved in binding to a particular partner. Post translational modifications sites are 
represented by vertical ticks. Experimentally characterized regions of disorder (red) and order (blue) are indicated by the hor-
izontal bar. Finally, predictions of disorder (scores > 0.5) and order (scores < 0.5) are shown for two PONDR predictors: 
VLXT (solid line) and VSL2P (dashed line). All, features are presented to scale, as indicated by the horizontal axis. The p53 
interaction partners and post translational modification sites have been adapted from Anderson & Appella [55].
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(Figure 1, graph). The latter is one of the highest accuracy
prediction algorithms available [86], whereas the former
has been observed to be especially useful in identifying
binding regions within longer regions of disorder [87-89]
and to be much better at identifying such sites as com-
pared to a number of different disorder predictors [90].
Both predictors give good agreement with the experimen-
tal determination of intrinsic disorder [83,91-109], and in
the case of p53 both of their predictions agree well with
experimental characterization.
Analysis of associations involving p53 using 3D structures
The structures of 14 complexes between various regions of
p53 and unique binding partners have been determined
(Figure 1, horizontal bars). For 10 of these partners, the
interactions are mediated by regions experimentally char-
acterized as intrinsically disordered, where PONDR VL-XT
detects the majority of these binding regions as short pre-
dictions of order within a longer prediction of disorder.
These structures are complexes between p53 and endog-
enous partners: cyclin A [64], sirtuin [65], CBP [66],
S100ββ [67], set9 [68], tGcn5 [69], Rpa70 [70], MDM2
[71], Tfb1 [72], and itself [73]. The remaining 4 interac-
tions are mediated by the structured DBD, namely
between p53 and 3 endogenous partners – DNA [74],
53BP1 [75], and 53BP2 [76] – and one exogenous partner
– the large-T antigen (LTag) from simian virus 40 [79].
Protein complexes can be formed from the association of
structured proteins, by the folding of one disordered pro-
tein onto the surface of a structured partner, or by the cou-
pled folding and binding of intrinsically disordered
proteins [110-117]. Nussinov and collaborators [117]
showed that a plot of normalized monomer area (NMA)
versus normalized interface area (NIA) nicely separates
complexes formed from structured proteins as compared
to complexes formed from unfolded proteins by coupled
binding and folding. That is, associations of structured
proteins exhibit small NMAs and NIAs and so lie near the
origin of the NMA-NIA plot. Conversely, complexes
formed by coupled binding and folding have much larger
NMAs and NIAs, and so are spread out and lie far from the
origin of the NMA versus NIA plot. Indeed, a linear
boundary separates the two groups [117]. IT should be
emphasized that the NMA-NIA plot approach is a global
measure of a proteins order-disorder monomeric state,
and has not been characterized on local order-disorder
transitions (e.g. disordered binding loops in an otherwise
well ordered protein).
As described in more detail in the implementation, by
developing two separate NMA-NIA plots, one for each
partner of a complex (Figure 2A), and then by determin-
ing the distance to the linear boundary in each plot, a dou-
ble NMA-NIA plot (Figure 2B) can be produced.
Interacting pairs can be divided into the 3 groups given
above, namely: (1) both partners are structured (region (i)
Double NMA-NIA plot for p53 complexes Figure 2
Double NMA-NIA plot for p53 complexes. (A) The definition of boundary distance used in the double NMA-NIA plot, 
where ordered structures have a negative boundary distance and disordered structures have a positive boundary distance. (B) 
The double NMA-NIA plot for the p53 structures shown in Figure 1, with the exception of DNA-bound p53.
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of 2B), i.e. both distances are negative; (2) one partner is
structured and the second partner is disordered, i.e. the
ordered partner has a negative distance and the disordered
partner has a positive distance (regions (ii+ and ii-) of 2B);
and (3) both partners are intrinsically disordered, i.e.
both distances are positive (region (iii) of 2B).
A double NMA-NIA plot was calculated for 13 of the p53
complex structures (Figure 2B). The p53-DNA complex
was excluded since the NMA-NIA analysis is not relevant
for nucleic acids. In the general case, the distinction
between the distances of the two partners is arbitrary, so
that the double NMA-NIA plot is symmetric about the
diagonal. However, here we restrict the p53 distance to
one axis, so that group (2) is split into two sub groups
(regions (ii+ and ii-)): the p53 segment is disordered and
the partner is ordered (region (ii-)) and the p53 region is
ordered and the partner is disordered (region (ii+)). One
interaction, the formation of the p53 tetramer, is in the
third group (region (iii)) and so therefore likely involves
an association between two disordered partners. This is
consistent with experimental data [81]. At the opposite
side of the spectrum, the three protein-protein complexes
involving the p53 DBD domain are in group 1 (region
(iii)), indicating that all three are ordered prior to bind-
ing, which is consistent with the solution of structures for
identical or homologous monomeric domains (e.g. p53
DBD [118], 53BP1 BRCT domain [119], 53BP2 SH3
domain [120], and LTag [79]). The other nine p53 com-
plexes found so far in the PDB are all in the group 2 quad-
rant (that is, in region (ii-), and so all likely involve a
disordered region of p53 associating with a structured
partner. These results are likewise consistent with experi-
mental data. That is, these p53 regions are disordered in
the unbound state [81,82], and the isolated partners
appear to be structured: MDM2 [121], Rpa70 [70], Tfb1
[72], tGCN5 [122], Cyclin A/CDK2 [123], sirtuin [124],
CBP [125], S100ββ [126] and set9 [127]).
In summary, these data point out the importance of disor-
der-to-order transitions for many of the structurally char-
acterized interactions involving the p53 hub protein.
While many previous studies discuss these same interac-
tions, to our knowledge the importance of disorder has
not been emphasized in those previous studies.
Analysis of multiple specificities in the p53 C-terminus
So far, complexes involving one region of the p53
sequence bound to four different partners have been
determined and deposited in the PDB. This region is from
residue 374 to 388 in the p53 sequence bound to one of
the following: cyclin A [64], sirtuin [65], CBP [66], or
S100ββ [67]. The regions that mediate these interactions
and their respective secondary structures were mapped
precisely to the p53 sequence (Figure 3A). Although
slightly different residues of the p53 sequence are used in
Sequence and structure comparison for the four overlapping complexes in the C-terminus of p53 Figure 3
Sequence and structure comparison for the four overlapping complexes in the C-terminus of p53. (A) Primary, 
secondary, and quaternary structure of p53 complexes. (B) The ΔASA for rigid association between the components of com-
plexes for each residue in the relevant sequence region of p53. The two hatched bars indicate acetylated lysine residues.
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each interaction, there is a very high degree of overlap,
with a span of 7 core residues being the same (Figure 3A).
Interestingly, the four complexes display all three major
secondary structure types. The core span becomes a helix
when binding to S100ββ, a sheet when binding to sirtuin,
and a coil with two distinct backbone trajectories when
binding to CBP and cyclin A2 (Figure 3A).
Because the secondary structures are distinct, it seems
likely that p53 utilizes different residues for the interac-
tions with these four different partners. To examine this,
the buried surface area for each residue in each interaction
was quantified by calculating the ΔASA (Figure 3B). Dif-
ferent amino acid interaction profiles are seen for each of
the interactions, showing that the same residues are used
to different extents in the four interfaces. The particularly
large ΔASA peaks for K382 in complexes with CBP and sir-
tiun (indicated by the hatched bar) are due to extra buried
areas arising from the acetylation of this residue. This
highlights the importance of posttranslational modifica-
tion for altering PPI networks.
Analysis of multiple specificities of the p53 DBD
The p53 molecule contains another set of overlapping
interactions that contrasts with those at the C-terminus.
These interactions are mediated by the DNA binding
domain and include interactions with DNA [74], the
BRCT domain of 53BP1 [75], the SH3 domain of 53BP2
[76], and the large T-antigen (LTag) of Simian Virus 40
[79]. Here we compare these four interactions using the
methods described in Figure 4.
The structures of the p53-DNA, the p53-53BP1, the p53-
53BP2, and the p53-LTag complexes are shown (Figure
4B). While all of the ligands are different, they all bind to
basically the same region of p53.
Comparison of the interface profiles of the four com-
plexes (Figure 4A) shows a large difference in the pattern
of interface residues used by p53. For instance, there are
several residues at the N-terminal end of the DBD which
are only found in interaction with DNA. Similarly, inter-
face residues near the C-terminal end participate in bind-
ing to different extents in three interactions, but not at all
in the p53-53BP1 interaction. The differing usage of resi-
dues in each interaction is the most prevalent feature of
this data. However, there are also several residues contrib-
uting an exceptionally large amount of surface area in
each complex (e.g., M243 and R248).
While the focus of this paper is on the roles of disorder in
the interactions involving two different hub proteins, the
DNA binding domain of p53 presents the opportunity to
study structural changes involving one structured region
binding to several different structured partners. For this
purpose, we compiled a 4-panel set of plots for character-
izing the induced fit as one protein binds to different part-
ners (Figure 5). These panels show the average interface
area (Figure 5A), the standard deviation of the interface
area (Figure 5B), the differences in side chain conforma-
tion (Figure 5C), and differences in backbone conforma-
tion (Figure 5D). Furthermore, regions that are highly
exposed to solvent are also indicated (Figure 5, blue shad-
ing), so that structural differences due to interactions can
be distinguished from those due from intrinsic flexibility
– disordered loops – or crystallization artifacts.
This induced-fit profiles exhibit a number of interesting
features (Figure 5). The most striking of these is the region
from residue 240 to residue 250. This region shows a large
and variable interaction interface, which is associated
with large side chain and backbone conformational differ-
ences. This is true also of a smaller region around residue
120. Other interaction regions show only side chain con-
formational differences associated with variable interface
areas. Other conformational differences observed are lim-
ited regions of high solvent exposure, which suggests that
these changes are due the details of the crystallization con-
ditions more than interaction with a particular binding
partner.
Together, these results suggest that multiple partners of
p53 are accommodated by reusing similar binding inter-
faces. This is facilitated by small scale or large scale struc-
tural differences, which range from differences in side
chain conformation to backbone rearrangements. It
should be noted that this differs from our finding in a
more limited analysis on only the p53-53BP1 and -53BP
complexes [80].
Analysis of the multiple specificities of 14-3-3
Five different 3-D structures of the 14-3-3ζ protein bound
to distinct partners were found in PDB. These partners
include a peptide from the tail of histone H3 [128], sero-
tonin N-acetyltransferase (AANAT) [77], a phage display-
derived peptide (R18) [78], and motif 1 and 2 peptides
(m1 and m2, respectively) [61]. For AANAT, only the
region within the canonical 14-3-3 binding site is
included in our analysis with the globular region being
deleted. Two additional structures were not included
because they were either unsuitable for structural analysis
or were highly redundant with another structure. All pep-
tides are phosphorylated in their respective structures
except R18, which contains a glutamate in place of the
phosphoserine.
The five bound peptides sequences were aligned structur-
ally as described in the methods. Likewise, the 14-3-3
domain structures were independently aligned, without
considering the bound peptides. Next the 14-3-3 align-BMC Genomics 2008, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2164/9/S1/S1
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ment was anchored manually by the observed corre-
spondence of the bound peptide Cα atoms at the 0 and -1
positions and by extending the alignment without gaps
from the anchor positions, thereby giving the final struc-
tural alignment (Figure 6A). In terms of sequence, the R18
sequence has no identical positions to any other peptide.
The number of identities between the other peptides
range from 1 to 4.
The high overlap in the backbone trajectories of the 5 pep-
tides from position -3 to 1 but large divergences at either
end of the structural alignment (Figure 6A). This diver-
gence at the ends is apparent qualitatively in the superim-
posed structures of the five peptides (Figure 6B).
Structural divergence and sequence variability are loosely
correlated, where positions with 3 identical residues have
a lower divergence than those with no identical residues.
This suggests that 14-3-3 may use different binding pocket
residues to interact with different peptide residues. The
R18 sequence, which is divergent from the others, makes
a large contribution to the estimated RMSF values (indi-
cated by the cross-hatched bars, Figure 6A).
p53 DBD interaction with different binding partners Figure 4
p53 DBD interaction with different binding partners. The interaction profiles (A) and rendered structures (B) for the 
four unique complexes of the p53 DBD. Rendered structures depict p53 as a ribbon and each interaction partner as a molecu-
lar surface. The interaction profile-structure pairs are (from top to bottom): p53-DNA, p53-53BP1, p53-53BP2, and p53-sv40.
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The factors contributing to the ability of 14-3-3 to bind to
distinct peptides were estimated by a detailed structural
analysis. The peptide binding residues of 14-3-3 are
located primarily in a central cleft, made up of four helices
(Figure 7A), which has been noted previously by several
researchers. The standard deviation of ΔASA for the pep-
tide binding residues (Figure 7B) show that the residues
with the most binding variability are located at either end
of the central cleft, which is consistent with the variation
of peptide backbone trajectories in these regions. Back-
bone variability in bound 14-3-3 structures (Figure 7C) is
restricted to the ends of most of the binding cleft helices.
These observations suggest that large a conformational
change in 14-3-3 is not necessary for multiple specificities,
although some small adjustments at the ends of binding
helices may be necessary.
To assess the role of side chain conformational changes in
peptide binding, the RMSF of side chain atoms was calcu-
lated (Figure 7D). The side chain RMSF and standard devi-
ation of ΔASAs give similar indications for many binding
site residues, where residues used inconsistently across
multiple complexes are the most likely to undergo confor-
mational rearrangement. These are the same residues that
are located at the broadest parts of the binding site. How-
ever, a few residues deep in the binding grove show both
consistent participation in the binding interface and vari-
able side chain conformation. These observations suggests
that the primary, high level mechanisms of 14-3-3 multi-
ple specificity are a broad binding site that allows multiple
trajectories (and therefore interaction with different resi-
dues) and side chain rearrangement to accommodate dif-
ferent peptide sequences.
Comparison of residue interactions with structural differences for bound p53 DBD Figure 5
Comparison of residue interactions with structural differences for bound p53 DBD. The average (A) and standard 
deviations (B) were calculated over the four interaction profiles of the p53 DBD shown in Figure 4. These are shown aligned 
with the side chain RMSF (C) and the backbone RMSF (D) calculated from the four structures of bound p53 DBD. Regions of 
residues that are highly exposed to solvent in all complex structures are indicated by the blue-shaded regions.
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To further analyze the conformational changes in 14-3-3
upon binding to its multiple partners, we show the 4-
panel induced-fit profile described above (Figure 8). Con-
trary to the results seen for the p53 DBD, 14-3-3 is much
more static in its multiple interactions. All regions dis-
playing large conformational differences across bound
complexes are also highly exposed to solvent and play no
direct role in mediating binding to any peptide. The plots
do show several small scale structural differences – side
chain rearrangements – associated with variable participa-
tion in peptide binding, particularly in the regions 40-60
and 215-230.
14-3-3 binding to two different partners
To gain further insight into 14-3-3 binding to different
partners, we compared a pair of 14-3-3 binding peptides
in detail. These two peptides, m1 and m2, were derived
from two motifs, identified through the screening of pep-
tide libraries for sequences that bound to all 14-3-3 iso-
forms [62]. These two peptide structures have been
compared previously [61], but here we reanalyze these
structural data from the order-disorder point of view.
As noted previously [61], the backbone traces of the two
peptides are noticeably different even though the m1 and
m2 peptides bind to essentially the same region of 14-3-
3ζ (Figure 9A and B, respectively). Examining the side
chain interactions of these peptides with specific 14-3-3
residues (Figure 9C and D) shows that there is difference
in the location and identity of the residues involved,
which is consistent with the aggregate findings (Figures 7
and 8). Similarly, distinctive hydrogen bonding patterns
are exhibited between the two peptides and 14-3-3ζ and
between the two peptides and bound water (Figure 9C
and D). Since a cardinal feature of a structured protein is
internal satisfaction of hydrogen bond donors and accep-
tors, these data are both consistent with the peptides
being from unstructured regions of protein before bind-
ing.
The above data on the complexes suggest that 14-3-3ζ has
distinct conformations when bound to the two different
peptides. Overlaying the backbone structures of the four
binding helices from both complexes – based on a pair-
wise alignment of the complete domains – shows only
minor variability in conformation, with the most occur-
ring at the helix spanning residues 216 to 228 (Figure 9E).
Sequence and structure for five peptides bound to 14-3-3ζ Figure 6
Sequence and structure for five peptides bound to 14-3-3ζ. (A) Sequence alignment of the bound peptides and the 
RMSF of their conformations. Solid grey bars give the RMSF for four peptides – excluding R18 – and the hatched bars give the 
RMSF for all five peptides. (B) Aligned ribbon representations of the structures of the five peptides, which were aligned through 
multiple alignment of their respectively bound 14-3-3 domains, show along with a representative ribbon representation of a 14-
3-3 domain.
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Finally, comparison of side chain conformation in the
two complexes shows significant differences in several of
14-3-3ζ side chains (Figure 7F, residues outlined in red
show significant movement) and several other minor dif-
ferences. Overall, these data suggest that a difference in
the conformations of some side chains with rather less dif-
ference in backbone conformations is sufficient to accom-
modate the binding of two different phosphopeptides by
the 14-3-3ζ molecule.
Discussion
Use of disordered regions for binding
The large majority of the binding sites on the p53
sequence map to the disordered regions of this protein
(Figure 1), indicating that intrinsic disorder commonly
provides the binding sites for the various partners that
associate with p53. Recent bioinformatics investigations
suggest that the majority use of disorder for binding to
multiple partners is quite likely to be a general result [37-
41].
The p53 binding sites are often indicated on the order-dis-
order predictions as dips, in other words as short seg-
ments with structure tendency flanked by regions of
disorder tendency on both sides. Starting from this obser-
vation, we previously developed a predictor of such
regions, which we called molecular recognition features,
or MoRFs, because such regions “morph” from disorder to
order upon binding [87,88]. Others have used the
PONDR VL-XT order/disorder plots or MoRF predictors to
identify potential binding sites that were subsequently
verified by laboratory experiments [89,129]. Indeed, for
some of these predicted examples, the regions did indeed
form helix upon binding to their partners [130,131]. By
greatly enlarging the training set, we recently improved
the MoRF predictor. Interestingly, when tested against sev-
eral order-disorder predictors including ones from other
laboratories, PONDR VL-XT, gave the clearest indication
of binding sites within disordered regions [90].
Others developed a sequence-based approach to identify
short, conserved recognition sites, called eukaryotic linear
motifs (ELMs) [132,132-134]. While MoRFs are identified
by general order/disorder tendencies and while ELMs are
identified by motif discovery from sequence analysis, the
resulting binding sites identified by both methods share
several features [135]. The use of different residues in the
same disordered fragment for one-to-many signaling
leads to a potential problem with the ELM model. That is,
the concept behind ELMs is that each ELM uses a common
set of amino acids for binding to different partners. These
common amino acids therefore show up as an over-repre-
sented pattern leading to a “linear motif”. What if a region
used to bind to multiple partners uses different secondary
structures and different amino acids? In such a case, the
residues in the “linear motif” would not necessarily be
over-represented. It will be interesting over time to deter-
mine whether ELMs having stronger signals use a reduced
set of structures for their interactions.
While the observed binding sites in the disordered regions
of p53 have a localized tendency for ordered structure, not
all disorder-associated binding sites exhibit such features.
We have found many binding sites that are associated
with high disorder prediction values across the entire
spans of the binding sites, one example of which was
recently published [136]. Many of these dipless MoRFs
form irregular structures upon binding with their partners,
and often such binding regions are rich in proline. Our
recent study of the complexes that form when various dis-
Peptide binding residues of 14-3-3ζ Figure 7
Peptide binding residues of 14-3-3ζ. (A) The Cβ atoms 
of all residues involved in binding in any of the five peptide 
bound structures are shown (red) along with the rest of the 
backbone (light blue ribbon). (B) The standard deviation in 
the area bound on complex formation is displayed by color-
ing the Cβ atoms of peptide binding residues on a gradient, 
from a standard deviation of 0Å2 (blue) to 10Å2 and greater 
(red). (C) The backbone RMSF of the 14-3-3 domain calcu-
lated over Cα atoms displayed as a color and radius gradient, 
from an RMSF of 0Å (blue, 0.25Å) to an RMSF of 2.0Å and 
greater (red, 2.0Å). (D) The side chain RMSF is displayed by 
coloring the Cβ atoms of peptide binding residues on a gradi-
ent, from a RMSF of 0Å (blue) to an RMSF of 0.50Å and 
greater (red). All parameters were calculated using all five of 
the peptide-14-3-3 complexes.
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ordered segments bind to ordered partners indicates that
the disorder-associated binding regions have distinct
sequence features, even when the bound structure is irreg-
ular or sheet instead of helix, and so it should be feasible
to develop a specific predictor for each of the different
types of MoRFs [137].
One-to-many signaling
Date hubs bind to different proteins at different times.
Figure 3 shows how a single region of p53 binds to four
different partners. The amino acids involved in each inter-
action show a significant overlap and no two of these
interactions could exist simultaneously. Furthermore, the
same residues adopt helix, sheet, and two different irregu-
lar structures when associated with the different partners.
Finally, the same amino acids are buried to very different
extends in each of the molecular associations. These
results show very clearly how one segment of disordered
protein can bind to multiple partners via the ability to
adopt distinct conformations.
The idea that one segment of protein can adopt different
secondary structures depending on the context is not new.
Many unrelated proteins have identical subsequences of
length six, and sometimes even up to length eight, with
the same sequences often adopting different secondary
structures in different contexts [138,138-140]. Such
sequences have been called chameleons for their ability to
adopt different structures in different environments [139-
145]. Chameleon behavior could be an important feature
Comparison of residue interactions with structural differences for bound 14-3-3ζ Figure 8
Comparison of residue interactions with structural differences for bound 14-3-3ζ. The average (A) and standard 
deviations (B) were calculated over the five 14-3-3ζ-peptide interaction profiles. These are shown aligned with the side chain 
RMSF (C) and the backbone RMSF (D) calculated from the five structures of bound 14-3-3ζ. Regions of residues that are highly 
exposed to solvent in all complex structures are indicated by the blue-shaded regions.
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Detailed analysis of 14-3-3ζ peptide binding Figure 9
Detailed analysis of 14-3-3ζ peptide binding. The m1 peptide (A, orange ribbon) and m2 peptide (B, red ribbon) bound to 
14-3-3 (A and B, shown by the green and blue surface, respectively). Details of 14-3-3 peptide binding are shown by a chemical 
schematic for the m1 peptide (C) and the m2 peptide (D), where both crystallographic waters (blue) and implicit waters (red) 
are shown. (E) Superposition of the backbone atoms from the 4 helices with the primary peptide binding residues for m1 
(green) and m2 (blue) bound 14-3-3. (F) Superposition of ribbons of the same 4 helices showing the side chains of the residues 
that participate in m1 (green) and/or m2 (blue) binding.
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that enables one disordered region to bind to multiple
partners. With different secondary structures and with dif-
ferent side chain participation in the different complexes,
it is as if one sequence can be “read” in multiple ways by
the various binding partners.
Chameleon behavior occurs for short peptides (octam-
ers), for longer protein fragments and even for entire pro-
teins. For example, the 17 residues-long arginine-rich
RNA binding domain (residues 65–81) of the Jembrana
disease virus (JDV) Tat protein recognizes two different
transactivating response element (TAR) RNA sites, from
human and bovine immunodeficiency viruses (HIV and
BIV, respectively). The JDV segment adopts different con-
formations in the two RNA contexts and uses different
amino acids for recognition [142]. In addition to the
above conformational differences, the JDV domain
requires the cyclin T1 protein for high-affinity binding to
HIV TAR, but not to BIV TAR [142]. Another protein with
chameleon properties is human α-synuclein, which is
implicated in Parkinson's disease and in a number of
other neurodegenerative disorders known as synuclein-
opathies. This protein may remain substantially unfolded,
or it may adopt an amyloidogenic partially folded struc-
ture, or it may fold into α-helical or β-strand species,
including both monomeric and oligomeric species. In
addition, this protein can form several morphologically
different types of aggregates, including oligomers (spheres
or doughnuts), amorphous aggregates, and amyloid-like
fibrils [34].
Such chameleon sequences likely underlie the multiple
specificity binding sites common in p53. For a quick cal-
culation of the implied degree of interface overlap,
assume that each residue in a region has equal probability
to interact with a partner and consider the C-terminus of
p53. The disordered C-terminus (~100 residues) associ-
ates with at least 44 distinct partners. The average length
of a binding site in this region is ~14 residues, which
means that on average only 100/14=7 partners bind at any
given residue in the C-terminus. This simple back-of-the-
envelope calculation suggests that multiple specificity
sequences may be the rule for p53 interactions, rather
than a curiosity of a single region. However, available data
suggests that interactions do not overlap in a random
fashion, but rather interactions are localized to specific
regions. For example, consider that the majority of the
structures available for the C-terminus of p53 involved the
same region of sequence. Therefore, the back-of-the-enve-
lope calculation provides an approximate minimum
degree of overlap, where the actual degree of overlap is
likely much higher. This idea, which is an extension of a
previous proposal [117], further suggests a general mech-
anism by which hub proteins could bind to such a large
multitude of partners, which cannot be explained from
the view point of interaction between two structured pro-
teins [51].
Finally, the p53 DBD offers a counter example to the dis-
order-based view of date hubs. That is, it uses the same or
similar face of its globular structure to bind to multiple
partners. While the p53 DBD is a folded protein, it does
exhibit some remarkable structural differences when
bound to difference partners. It seems unlikely that these
local regions of the p53 DBD structure are well folded in
isolation, otherwise the association rate of some or all of
these complexes would be relatively low. This idea is sup-
ported by the finding that the p53 DBD is only marginally
stable at physiological temperature [146]. Therefore, it is
plausible that these regions of the monomeric DBD are
only transiently folded in solution, where crystallization
conditions cause a shift toward the folded state in mono-
meric crystal structures. The double NIA-NMA plot data
(Figure 2B) does not contradict this idea, since it is limited
to global analysis and this idea only applies to local
regions of the DBD. This idea is conjecture and further
experimental or simulation evidence is needed to test this
idea. In any event, however, the p53 DBD demonstrates
that even proteins generally thought to be well folded,
structural changes can still occur in association with mul-
tiple specificity.
Many-to-one signaling
In 14-3-3, a common binding groove in a structured
dimeric protein can be fitted by multiple, distinct
sequences provided by many different binding partners. A
recent bioinformatics study [63] found that14-3-3 pro-
teins, and the 14-3-3 binding regions in particular, are
predicted to be highly disordered by multiple disorder
prediction methods. The authors proposed that 14-3-3
recognition generally involved coupled binding and fold-
ing of the recognition region. Our results support this con-
clusion because the backbone of m1 and m2 peptides are
highly hydrated in the bound state (Figure 9C and D),
indicating that the binding peptide is likely to be unstruc-
tured prior to binding [83].
One idea is that 14-3-3 holds its bound partner in a non-
active state [63]. Even though 14-3-3 likely binds to disor-
dered regions in its partners (data herein and [63]), this
idea of blocking the active structure could still be true. For
example, the productive state of 14-3-3's partner might
involve the binding of the partner to a second partner via
the same disordered region that binds to 14-3-3, in which
case 14-3-3 binding would prevent the formation of the
productive complex. Another possibility is that the disor-
dered region exhibits an equilibrium between a bound
state that activates the protein and an unbound state that
inactivates the protein. The association of the unbound
disordered region with 14-3-3 would then hold 14-3-3'sBMC Genomics 2008, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2164/9/S1/S1
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partner in the non-productive state as proposed previ-
ously.
We previously suggested that disordered segments with
different sequences could use their flexibility to bind to a
common binding site, thereby facilitating many-to-one
signaling [35]. The multiple recognition of 14-3-3
depends on this mechanism to a considerable degree,
with the different peptides taking different paths through
the binding cleft and interacting with binding site residues
in distinct ways (Figure 6B).
In addition, structured proteins also have a degree of flex-
ibility, and so the binding site backbone and side chain
residues can undergo shifts (induced-fit mechanisms) to
help accommodate interactions with distinct sequences
(Figure 6 and 8). Thus, induced-fit mechanisms are
important for structured protein interactions with differ-
ent partners whether the partners are structured or intrin-
sically disordered.
The induced-fit mechanisms observed for 14-3-3 and the
DNA binding domain of p53 are commonly observed in
other situations. For example, tethering, in which a pep-
tide is covalently linked to its protein target to allow detec-
tion of low affinity interactions, often results large-scale
side chain movements concomitant with peptide binding
[147]. Also, when many different MoRFs and their bind-
ing partners are examined, induced-fit movements in the
structured partners are very commonly observed [137].
Similarly, small backbone shifts and side chain conforma-
tional changes are both important for 14-3-3's ability to
bind multiple partners. For all of these examples, the asso-
ciations involve coupled binding and folding for the dis-
ordered peptide partner coupled with a near universal
classical induced fit for the structured side of the partner-
ship.
One-to-many signaling vs. many-to-one signaling
The p53 C-terminus and 14-3-3 use intrinsic disorder dif-
ferently with regard to enabling multiple binding specifi-
cities. In p53, drastic conformational changes enable
distinct surfaces to be exposed to binding partners. In 14-
3-3, subtle differences in 14-3-3 conformation and pep-
tide binding locations enable multiple specificities. Why
would nature use one mechanism rather than the other
for a particular biological role? The interactions of p53
serve to activate or inhibit its primary role as a transcrip-
tion regulator, while 14-3-3 alters the functions or subcel-
lular localization of many proteins. From this, one can
make some highly speculative proposals: (1) disorder
binding regions play a passive role in regulation by pro-
viding a specific binding site – i.e. the disordered regions
are the identification sites of the protein to be regulated
[148] – and (2) ordered proteins play the active role – i.e.
altering the activity of the proteins they bind to – where
recognition of disordered regions allows for a generalized
specificity so that a single protein can alter the activity of
many others. Validation of the accuracy and generality of
these ideas requires further study.
Conclusions
Here we have examined the mechanisms of multiple spe-
cificities in two date hub-like hub proteins. Evidence here
and elsewhere [37-41], suggests that disordered regions
may be an extremely common mechanism by which hub
proteins bind to their multitude of partners. The specific
examples of p53 and 14-3-3 contrasts the mechanisms by
which disorder facilitates multiple recognition, where the
former involves drastic conformational differences in a
single disordered region and the later involves a variety of
subtler changes in order to recognize multiple disordered
regions. Finally, it is proposed that the differences
between the binding of the disordered region of p53 and
the binding of disordered regions to 14-3-3 may have
implications for the biological roles of both types of inter-
actions.
Methods
PONDRs VL-XT and VSL1
Predictions of intrinsic disorder in HPV proteins were per-
formed using a set of PONDR® (Predictor Of Natural Dis-
ordered Regions) predictors, VL-XT and VSL2. PONDR®
VL-XT integrates three feed forward neural networks: the
Variously characterized Long, version 1 (VL1) predictor
from Romero et al. 2001 [84], which predicts non-termi-
nal residues, and the X-ray characterized N- and C- termi-
nal predictors (XT) from Li et al. 1999 [149], which
predicts terminal residues. Output for the VL1 predictor
starts and ends 11 amino acids from the termini. The XT
predictors output provides predictions up to 14 amino
acids from their respective ends. A simple average is taken
for the overlapping predictions; and a sliding window of
9 amino acids is used to smooth the prediction values
along the length of the sequence. Unsmoothed prediction
values from the XT predictors are used for the first and last
4 sequence positions.
The recently developed Various Short-Long, version 1
(PONDR®-VSL1) algorithm is an ensemble of logistic
regression models that predict per-residue order-disorder
[85,150]. Two models predict either long (>30 residues)
or short (<15 residues) disordered regions based on fea-
tures similar to those used by VL-XT. The algorithm calcu-
lates a weighted average of these predictions, where the
weights are determined by a meta-predictor that approxi-
mates the likelihood of a long disordered region within its
61-residue window. Predictor inputs include PSI-blast
profiles [151], and PHD [152], and PSI-pred [153] sec-
ondary structure predictions.BMC Genomics 2008, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2164/9/S1/S1
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Structure surface and complex interface analysis
Solvent accessible surface area (ASA) was calculated from
atomic protein structure numerically using the double
cubic lattice method [154] as implemented in the Bio-
chemical Algorithms Library [155]. Using this algorithm,
ASA of residues and entire chains can be calculated.
To determine interface areas, for example between two
chains, the ASA of each individual chain is calculated, as
well as the ASA of the complex. The interface area is then
calculated as the change in ASA (ΔASA), i.e. the sum of the
individual chain ASA minus the complex ASA. Residues
directly involved in interactions were identified from
molecular structures as residues with a ΔASA greater than
1 Å2 [112,113]. All calculations used a probe radius of 1.4
Å, which roughly corresponds to the size of a water mole-
cule.
Order-disorder evaluation from known structure
The work of Gunasekaran et al. has previously shown that,
in many cases, the order-disorder state of a protein prior
to complex formation is reflected in the complex structure
[117]. Specifically, a plot of the normalized monomer
area (NMA) – ASA divided by the number of monomer
residues – versus the normalized interface area (NIA) –
ΔASA divided by the number of monomer residues –
effectively distinguishes between ordered and disordered
monomers using a linear boundary. This effectiveness of
this NMA-NIA plot has been validated on an expanded
dataset and an optimal linear boundary has been esti-
mated and evaluated (Oldfield et al., manuscript in prep-
aration). The equation for the novel boundary is:
Since the NMA-NIA plot can only represent one partner of
a complex, the double NMA-NIA plot was developed to
simultaneously represent both monomers of a binary
complex – or complexes that can be treated as binary, such
as two monomers bound to a dimer. Rather than plotting
the NMA and NIA directly, the Euclidean distance to the
order-disorder boundary is calculated, where disordered
monomers have a positive distance and ordered mono-
mers have a negative distance. Then the boundary dis-
tances of each monomer in a binary complex can be
plotted against each other to give an overall order-disor-
der prediction for the complex. The double NMA-NIA plot
is covered in more detail elsewhere (Oldfield et al., man-
uscript in preparation).
Other structure calculations
The root mean squared fluctuation (RMSF) is a com-
monly used measure of variability across multiple struc-
ture alignments. Here, RMSF of the protein backbone is
approximated as the RMSF of the Cα atoms. The equation
used is
where   is the position vector of the ith Cα atom of the
jth complex and   is the averaged position for the ith
amino acid from the multiple sequence alignment of N
structures. The program MultiProt [156] was used to gen-
erate the multiple sequence alignments for RMSF calcula-
tion and structure rendering.
To estimate side chain conformation variability among
multiple protein structures, the RMSF of side chain resi-
dues was calculated. In this calculation, the residue atoms
Cα,Cβ, backbone carbonyl carbon, and backbone nitrogen
were used to align a residue to a selected reference residue
of the same type. Thus aligned, the RMSF was calculated
over side chain carbons beyond the Cβ. Consequently, no
side chain RMSF was calculated for Glycine or Alanine res-
idues. The RMSF was also corrected for the number of
atoms in the side chain beyond the Cβ.
The solvent accessibility of individual residues was calcu-
lated relative to an extended Gly-X-Gly model peptide
[157], which gives a conservative estimate of relative sol-
vent exposure, i.e. underestimates relative solvent expo-
sure. Residues exposed to solvent were defined as those
with an accessible surface area at least 40% of that of the
reference area for that residue type. This cutoff is arbitrary,
but cutoffs for solvent exposed residues as low as 20%
have been used by others, e.g. [158]. Solvent exposures
were calculated in the context of binary complexes, which
is valid for p53 complexes. In 14-3-3 complexes, 14-3-3
forms homotypic dimmers in addition to binding to
phosphopeptides, so residues found to be highly solvent
exposed are either actually exposed to solvent or involved
in the homodimer interface.
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